Bulimia nervosa is an eating disorder, in which a person eats too much food in a short period of time. Eating disorders are often associated with mental disorders such as depression, anxiety, obsessive-compulsive disorder (OCD), and others. There is no specific treatment available for the treatment of bulimia nervosa. Furthermore, treatment options such as anti-depressants, antipsychotic, tests, and behaviors are currently the treatment for bulimia nervosa.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4323
The COVID-19 epidemic is expected to disrupt the global market for the treatment of bulimia nervosa during the forecast period. According to the Indian Journal of Medical Sciences, on June 6, 2020, the COVID-19 epidemic affected the conduct of clinical trials due to unavailability of laboratory staff, travel restrictions, availability of research products, and more. These challenges are obstacles to developing new treatments for bulimia nervosa.
According to the National Center for Biotechnology Information, on August 24, 2020, as a result of the COVID-19 epidemic, the government imposed restrictions on various parts of the world. This has led to the decline of all businesses, which has been a force to increase unemployment. In addition, a lack of communication has led to growing feelings of anxiety and depression. For instance, according to the Center for Disease Control and Prevention (CDC), on April 4, 2020, cases of depression in the US have tripled during the COVID-19 epidemic compared to 2019, the causes of bulimia nervosa, among of people.
The global bulimia nervosa treatment is estimated to be valued at US$ 455.7 Mn in 2020, and is expected to exhibit a CAGR of 5.2% over the forecast period (2020-2027).
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4323
Increased introduction of the product for psychiatric treatment among people is expected to stimulate growth of the global bulimia nervosa treatment market in the forecast period. Market players indulge in product launches, which are expected to stimulate the growth of the global bulimia treatment market in the forecast period. For instance, in 2019, Lupine Limited introduced a standard type of antidepressant Fluoxetine tablets 10 mg and 20 mg in the U.S. market. Fluoxetine pills have been shown to treat bulimia nervosa, panic disorder, major depression, and more.
Moreover, increased product approval for regulatory authorities is expected to boost market growth over the forecast period. Market players are working to get approval from regulatory authorities, which is an important step in introducing a product to the market. For instance, on April 9, 2020, Aurobindo Pharma received a U.S. permit. The product is a standard version of Eli Lily Pills and Company Prozac.
Lack of appropriate reimbursement policies for the treatment of eating disorders is expected to hinder the growth of the global bulimia nervosa treatment market in the forecast period. For instance, according to the National Eating Disorders Associations, annually, in the U.S., the total cost of treatment for eating disorders is worth US $ 30,000 per patient. Even if there is insurance, patients should pay extra for treatment. In addition, according to the same source, in the US, approximately 54,000 were admitted to the emergency department and 23,500 patient visits due to eating disorders during the 2018-2019 season, costing about US $ 29 million and US $ 209 million respectively. .
Moreover, the lack of drugs in the treatment of bulimia nervosa and the lack of awareness about treatment options among people are factors that are expected to hinder the growth of the global bulimia treatment nasal treatment in the forecast period.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/bulimia-nervosa-treatment-market-3583
North America is expected to hold a high position in the market for the treatment of bulimia nervosa in the forecast period, due to the increase in eating disorders in the region. For instance, according to an article published in the Biological Psychiatry Segment of Elsevier Journal: 2018, in the U.S., 36,309 adults with an eating disorder were hired to study the prevalence of bulimia nervosa in humans. It is estimated that, of educated adults, 0.80%, 0.28%, and 0.85% of U.S. adults. They were suffering from anorexia rhinos, bulimia nasal congestion, and anorexia nervosa.
Europe is also a market for bulimia nervosa, thanks to an increase in research activities to develop new treatments for foodborne illness. For instance, on March 2, 2020, the National Institute for Health Research (NIHR), in collaboration with the Eating Disorders Genetics Initiative (EDGI), recruited 10,000 people to study nutrition, especially bulimia nervosa, to help develop new treatments to improve the lives of patients with an eating disorder.
By Treatment Type:
- Drug Treatment: Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), Benzodiazepines, Tricyclic Antidepressants, Others.
- Non-drug Treatment: Nutritional Therapy, Behavioral Therapy, Others.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/4323
By Route of Administration:
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies.
Some of the key players operating in the global bulimia nervosa treatment market include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy’s Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027